Noteworthy

Dec 01, 2010
Pharmaceutical Executive
The strict regulatory divide between market authorization and price reimbursement iscrumbling in the US. Is industry prepared to adapt or challenge?
Dec 01, 2010
Pharmaceutical Executive
By Pharmaceutical Executive Editors
Pharma sets the pace for China's ambitious new innovation agenda
Dec 01, 2010
Pharmaceutical Executive
42 of the best new drugs in development–or parked at the FDA
Dec 01, 2010
Pharmaceutical Executive
Pharm Exec's Pipeline Report 2021
Dec 01, 2010
Pharmaceutical Executive
Pharm Exec's Pipeline Report 2019
Dec 01, 2010
Pharmaceutical Executive
Pharm Exec's Pipeline Report 2022
Dec 01, 2010
Pharmaceutical Executive
By Pharmaceutical Executive Editors
Outgoing EMA Director Thomas Lonngren discusses a decade at the helm of Europe's top regulatory office
Dec 01, 2010
Pharmaceutical Executive
Pharm Exec's Pipeline Report 2013
Dec 01, 2010
Pharmaceutical Executive
Putting science front-and-center in the design of patient adherence programs can lead to a better understanding of the commitment required to get patients to take their medicine
Dec 01, 2010
Pharmaceutical Executive
Pharm Exec's Pipeline Report 2011
native1_300x100
lorem ipsum